ViiV Seeks Speedy EMA Review For Last-Resort HIV Drug

US Filing For Fostemsavir Expected This Year

 
• By Neena Brizmohun

ViiV Healthcare has asked the European Medicines Agency to accelerate its review of fostemsavir when the company files for pan-EU market approval of the product.

Cells_HIV
Fostemsavir is for HIV patients who have become resistant to other treatments • Source: Shutterstock

More from Europe

More from Geography